A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell Transplantation
Study of VOR33 in Patients with Acute Myeloid Leukemia (AML)
Sponsor: Vor Biopharma
Enrolling: Male and Female Patients
IRB Number: AAAU4826
U.S. Govt. ID: NCT04849910
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: You are being asked to take part in this study because you have acute myeloid leukemia (AML). Vor Biopharma, is a company that is testing a possible new treatment for AML. This possible new treatment, is VOR33. In this study, your blood-forming stem cells will be genetically modified to become VOR33. VOR33 has not been approved by the Food and Drug Administration (FDA). This is a first time VOR33 is being studied in humans. The sponsor of this study is looking to find out if VOR33 is safe.
This study is closed
Investigator
Markus Mapara, MD
Do You Qualify?
Are you between the ages of 18-70? Yes No
Have you been diagnosed with Acute Myeloid Leukemia (AML)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE